secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001213900-25-075034
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4
--------------------------------------------------------------------------------

- Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.
- Cash and equivalents $6.1M at June 30; raised $12.5M in gross financings during the quarter.
- LYMPHIR launch for cutaneous T-cell lymphoma planned Q4 2025; manufacturing and distribution agreements in place.
- Citius Oncology raised additional $9M in July 2025 to fund pre-launch activities.
- Mino-Lok discussions with FDA continue; evaluating best path forward for antibiotic lock solution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/0001213900-25-075034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/ea0252899-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer